PTC (NASDAQ: PTC) today announced advancements to its application lifecycle management (ALM) portfolio with the release of ...

PTC (NASDAQ: PTC) will release its fiscal 2026 first quarter and on Wednesday, February 4 th after the stock market closes.

Conference draws participants from more than 60 countries; demand for leadership programs reaches capacity From sold ...

Founded in 1985, the Boston, Massachusetts-based PTC Inc. (PTC) provides software solutions and services globally that aid ...

PTC Therapeutics (PTCT) beats 2025 revenue guidance, details Evrysdi royalties and Sephience growth, and sets 2026 outlook.

Shares of PTC Therapeutics jumped 15% on Jan. 8 to $20.65, after the maker of Duchenne muscular dystrophy drug Emflaza told investors it expected its revenues to rise 135% year over year for 2017 and ...

PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...

Welcoming back in-person delegates to its LiveWorx conference for the first time since the pre-pandemic days of 2019, and noting that the company finds itself in one of the greatest periods of change ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

Shares of PTC Inc. PTC shed 1.18% to $171.52 Friday, on what proved to be an all-around great trading session for the stock ...